Screening for HIV-specific T-cell responses using overlapping 15-mer peptide pools or optimized epitopes

AIDS

Volumn 18, Issue 11, 2004, Pages 1595-1598

  Beattie, Tara ^a   Kaul, Rupert ^b   Rostron, Tim ^a   Dong, Tao ^a   Easterbrook, Philippa ^c   Jaoko, Walter ^d   Kimani, Joshua ^d   Plummer, Francis ^e   McMichael, Andrew ^a   Rowland Jones, Sarah ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

^c Caldecot Centre   (United Kingdom)

^d UNIVERSITY OF NAIROBI   (Kenya)

^e UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PEPTIDE;

AMINO TERMINAL SEQUENCE; ANTIBODY SCREENING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CLINICAL TRIAL; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; GENES, GAG; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE II;

EID: 3843107957     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000131362.82951.b2     Document Type: Article

References (28)

1. Pantaleo G, Demarest JF, Soudeyns H, Graziosi C, Denis F, Adelsberger JW, et al. Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature 1994, 370:463-467.
2. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999, 189:991-998.
3. Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothe BR, Vogel TU, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000, 407:386-390.
4. Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001, 193:169-180.
5. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997, 3:205-211.
6. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001, 412:334-338.
7. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997, 3:212-217.
8. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature 2001, 410:980-987.
9. Beattie T, Rowland-Jones S, Kaul R. HIV-1 and AIDS: what are protective immune responses? J HIV Ther 2002, 7:35-39.
10. Skurnick JH, Palumbo P, DeVico A, Shacklett BL, Valentine FT, Merges M, et al. Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. J Infect Dis 2002, 185:428-438.
11. Kaul R, Rowland-Jones SL, Kimani J, Dong T, Yang HB, Kiama P, et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8(+) responses. J Clin Invest 2001, 107:341-349.
12. Hanke T, McMichael AJ, Mwau M, Wee EG, Ceberej I, Patel S, et al. Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine 2002, 20:1995-1998.
13. McMichael A, Hanke T. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat Rev Immunol 2002, 2: 283-291.
14. Yang OO. Will we be able to 'spot' an effective HIV-1 vaccine? Trends Immunol 2003, 24:67-72.
15. Kaul R, Dong T, Plummer FA, Kimani J, Rostron T, Kiama P, et al. CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 2001, 107: 1303-1310.
16. Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, McElrath MJ. Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis 2003, 187:226-242.
17. Ferrari G, Neal W, Jones A, Olender N, Ottinger J, Ha R, et al. CD8 CTL responses in vaccines: emerging patterns of HLA restriction and epitope recognition. Immunol Lett 2001, 79:37-45.
18. Vogel TU, Horton H, Fuller DH, Carter DK, Vielhuber K, O'Connor DH, et al. Differences between T cell epitopes recognized after immunization and after infection. J Immunol 2002, 169:4511-4521.
19. Goulder PJ, Addo MM, Altfeld MA, Rosenberg ES, Tang Y, Govender U, et al. Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays. J Virol 2001, 75:1339-1347.
20. Kaul R, Rowland-Jones SL, Kimani J, Fowke K, Dong T, Kiama P, et al. New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol Lett 2001, 79:3-13.
21. Larsson M, Jin X, Ramratnam B, Ogg GS, Engelmayer J, Demoitie MA, et al. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS 1999, 13:767-777.
22. Promadej N, Costello C, Wernett MM, Kulkarni PS, Robison VA, Nelson KE, et al. Broad human immunodeficiency virus (HIV)-specific T cell responses to conserved HIV proteins in HIV-seronegative women highly exposed to a single HIV-infected partner. J Infect Dis 2003, 187:1053-1063.
23. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003, 77:2081-2092.
24. Sun Y, Iglesias E, Samri A, Kamkamidze G, Decoville T, Carcelain G, et al. A systematic comparison of methods to measure HIV-1 specific CD8 T cells. J Immunol Methods 2003, 272:23-34.
25. Draenert R, Altfeld M, Brander C, Basgoz N, Corcoran C, Wurcel AG, et al. Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods 2003, 275:19-29.
26. Bunce M, O'Neill CM, Barnardo MC, Krausa P, Browning MJ, Morris PJ, et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 and DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tiss Antigens 1995, 46:355-367.
27. Kaul R, Rowland-Jones SL. Methods of detection of HIV-specific CTL and their role in protection against HIV infection. In: HIV immunology database, vol. IV. Korber BTM, Haynes BF, Koup R, et al., editors. Los Alamos, NM, USA: Theoretical Biology and Biophysics Group T-10, Los Alamos National Laboratory; 1999. pp. 27-36.
28. HIV CTL epitope alignments. In: HIV molecular immunology database. Edited by Korber BTM, Haynes BF, Koup R, et al., editors. Los Alamos, NM, USA: Theoretical Biology and Biophysics Group T-10, Los Alamos National Laboratory; 1999. I-D-49.